Check Claims Before You Publish

Author Review — Jamie Rossjohn

Visual summary first: bibliometrics, representative high-impact studies, and a recent conceptual advance that expands TCR–pMHC paradigms.

Bibliometric snapshot (OpenAlex aggregate)

Visual: citations per representative year (OpenAlex counts_by_year subset)

Interpretation: strong citation peaks around mid-2000s–2010s reflecting multiple high-impact structural immunology contributions; continued activity into 2020s with sustained citation flux.

Data source: OpenAlex aggregated counts_by_year (selected years shown).

Scientific strengths (evidence-based)

• High-impact structural biology: multiple crystal structures of TCR–antigen-presenting molecule complexes (MR1, CD1b, MHC), producing mechanistic models that are widely cited and reproduced MR1–MAIT Nature 2012
• Consistent use of orthogonal methods: crystallography + SPR + mutagenesis + tetramer staining across studies increases confidence in structural/functional conclusions (example: GEM TCR–CD1b work includes sub‑µM KD measurements and donor tetramer data) GEM TCR–CD1b 2016
• Conceptual innovation: recent 2025 paper documents a novel peptide‑independent αβTCR docking mode (end-to-side), expanding the conceptual space of TCR–pMHC recognition and suggesting mechanistic connections to γδ TCR-like recognition modes G9 TCR–HLA‑DQ2 2025

Caveats, blind spots, and biases to watch for

• Generality vs single-clone findings: several high-visibility mechanistic papers (and the 2025 G9 TCR report) are based on limited donor numbers or a few TCR clones — robust for mechanistic truth but limited for population-level generality; additional donors/replicates needed to estimate prevalence.
• In vitro reconstitution artifacts: crystallography and SPR rely on soluble, reconstituted complexes and overexpression systems; while powerful, these can miss in vivo modulators (co-receptors, lipid composition, thymic selection), so physiological signaling consequences should be validated in complementary in vivo-like systems.
• Funding / industry links: the 2025 paper acknowledges Janssen support (declared) — declared funding does not imply compromised data, but potential bias pathways should be considered and data availability (PDBs 9EJG/9EJH/9EJI) supports independent validation G9 TCR–HLA‑DQ2 2025

Practical recommendations (for reviewers or collaborators)

1. Require population-level sampling when claiming biological prevalence — use multiple donors and orthogonal in vivo-like assays (primary T cells, organoids, or humanized mouse models) to show physiological relevance.
2. Encourage deposit of raw SPR sensorgrams, mutational raw data, and multi-angle validation datasets to improve reproducibility and independent re-analysis.
3. When reporting novel binding topologies, test signaling readouts in primary T cells with native co-receptors (CD4/CD8) and physiological expression levels to ensure biological significance.

Representative data links (for re-use / reproduction)

• MR1–MAIT Nature 2012 (DOI) — structural + functional foundational paper MR1–MAIT Nature 2012
• GEM TCR–CD1b 2016 (DOI) — high-resolution structural + SPR data GEM TCR–CD1b 2016
• G9 TCR–HLA‑DQ2 2025 (DOI) — structural PDBs 9EJG/9EJH/9EJI; recent conceptual advance G9 TCR–HLA‑DQ2 2025

Concluding evaluation (short)

Jamie Rossjohn is a world-class structural immunologist (very high bibliometric footprint, consistent high-impact papers, and continued conceptual innovation). Major strengths are rigorous structural approaches combined with biophysics and some human validation; main limitations are occasional single-donor or limited-sample claims for broad biological prevalence — which is fixable with expanded sampling and in vivo-like assays.